4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-111278
Chief Executive Officer sold 10,349 shares at $48.26 ($499,443)
- Chief Executive Officer acquired 20,625 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-14 | Exercise or conversion : show line 1 in the form | +20,625 | 256,183 | D | ||
| 2026-03-16 | Sale : show line 2 in the form | −10,349 | $48.26 | $499,443 | 245,834 | D |
| Open-market sales · 10,349 sh · avg $48.26 · $499,443 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-14 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −20,625 | 61,875 | D |
Loading xslF345X05/ownership.xml…